Display Settings:

Format

Send to:

Choose Destination
    Cancer Cytopathol. 2011 Oct 25;119(5):335-45. doi: 10.1002/cncy.20162. Epub 2011 Jun 29.

    Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings.

    Source

    Department of Diagnostic Pathology, Kurume University Hospital, Japan.

    Abstract

    BACKGROUND:

    Appropriate treatment of nonsmall cell lung cancer (NSCLC) depended on histologic type. The aim of this study was to evaluate the expression levels of Napsin A, thyroid transcription factor-1 (TTF-1), and p63 by immunostaining using CytoRich Red preserved cytocentrifuged bronchial brushings.

    METHODS:

    The expression levels of Napsin A, TTF-1, and p63 were semiquantitatively evaluated using proportion and intensity scores in 12 patients from whom both bronchial brushing cytology and bronchial biopsy samples had been obtained, as well as in a selection of 64 resected NSCLC tissue samples, and 8 normal or benign bronchial brushing cytology samples.

    RESULTS:

    The nuclear expressions of TTF-1 and p63 allowed for good visualization of cancer cells, whereas the cytoplasmic expression of Napsin A in cancer cells was often more difficult to evaluate because medium-sized and large macrophages also expressed Napsin A. Napsin A and TTF-1 were reliable adenocarcinoma markers, and p63 was a reliable squamous cell carcinoma marker in cytology, and histology samples. The average scores of Napsin A, TTF-1, and p63 were highly correlated in bronchial brushing cytology and bronchial biopsy samples, whereas TTF-1 expression was significantly lower than Napsin A expression in resected NSCLC tissue samples (P < .001).

    CONCLUSIONS:

    Immunostaining of bronchial brushings fixed with CytoRich Red was useful in determining histologic types in NSCLC. It was suggested that the panels of Napsin A, TTF-1, and p63 were effective in identifying histologic type in NSCLC, and that a combination of either Napsin A and p63 or TTF-1 and p63 should be chosen, depending on morphology.

    Copyright © 2011 American Cancer Society.

    PMID:
    21717589
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for John Wiley & Sons, Inc.

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk